Loading…
← CockpitCompetitor Analysis › 2733.T Arata CorporationOpen in the cockpit ↗

Arata Corporation2733.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Distributors
Momentum neutral 58
Mkt cap
$576M
US dollars, full cap
Free float
75%
of shares outstanding
$/day
$1.55M
20-day average traded
Fwd P/E
12.0×
forward earnings
ROIC−WACC
+0.2 pp
WACC 5.0%
Hurdle
-10 pp
Req g minus delivered
Next earnings
84 days
10 Feb 2027
Close · JPY¥2,602
1D+0.2%
1W+2.6%
1M+0.2%
3M+0.8%
6M-2.5%
YTD-15.5%
1Y-13.6%
ATR %2.3%
52w lowhigh17.8% off high

What Arata does

Employees: 3,008

Arata at a glance

Size Arata (2733.T) is a Japan Health Care company (Medical Distributors) with a market value of $576M, the 992nd largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,602 on 18 Nov 2026.

Performance Over six months the shares fell 2.5%, against -5.4% for the median peer and -1.4% for the Japan market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue grew 2.5% over the last twelve months (peer median +3.9%); the operating margin is 1.1% (peer median 2.3%).

Valuation It trades at 12.0× forward earnings against a peer median of 18.2× (2nd cheapest of 10).

Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -10 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.2 points above its cost of capital (5.0% WACC).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

909510010521 May 202621 Aug 202618 Nov 20262733.T 98Peer median 94
Six months, rebased to 100: Arata against the median of its 20 peers (local-currency closes).

Arata financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥1.02T¥1.00T¥986B¥944B¥892B
Revenue growth—+2%+4%+6%—
Gross profit¥98.7B¥97.3B¥96.2B¥92.4B¥86.8B
EBITDA¥16.8B¥18.1B¥19.8B¥19.1B¥17.4B
Net income¥8.80B¥10.1B¥10.4B¥10.3B¥8.22B
Free cash flown/a¥13.0B¥5.14B¥10.5B¥8.61B
Capital expendituren/a¥8.53B¥6.16B¥5.61B¥4.33B
Total debt¥53.0B¥53.7B¥36.0B¥38.4B¥43.3B

Quarterly statements and history in the cockpit →

Arata competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%600628301370605136603716NEU661700007841043151688366ENTEROARJO-B603368301166600713DOCM74762733.T6-month return →1-month return →
Up and to the right = strong over both horizons. Arata is the large dot.

Fundamentals: revenue growth against valuation

0%+20%20×40×NEU688366ENTEROARJO-B603368301166744774766005872733.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Arata is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%600628301370605136NEU0000784104688366ENTERO60336874473015842733.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Arata is the large dot.

Arata competitors and peer comparison

How Arata compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Arata against its 20 peers (data as of 18 Nov 2026)
Measure2733.TPeer medianRank in peer set
1-month return+0.2%-4.1%7th highest of 21
6-month return-2.5%-5.4%11th highest of 21
Distance from 52-week high-17.8%-22.4%9th highest of 21
Revenue growth (TTM)+2.5%+3.9%9th lowest of 21
Operating margin1.1%2.3%9th lowest of 21
Forward P/E12.0×18.2×2nd cheapest of 10
Growth the price implies (Req g, 7 yrs)-6.2%0.0%4th least demanding of 16
Growth delivered (Del g)+3.8%+5.7%7th lowest of 16
Hurdle (Req g minus delivered)-9.9 pp-5.0 pp4th least demanding of 16
ROIC minus cost of capital+0.2 pp-0.5 pp9th highest of 21
Net debt / EBITDA1.8×-1.2×3rd most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Arata 2733.TJapan$576M-3%+3%1%12.0×-6.2%+3.8%
Shanghai New World 600628.SSChina$573M-10%-2%6%n/a-1.6%+1.0%
GKHT Medical Technology 301370.SZChina$525M-24%-11%1%n/a13.1%+7.5%
Shanghai Lily & Beauty Cosmetics 605136.SSChina$449M-28%+5%2%n/a21.1%-18.1%
Thalys Medical Technology 603716.SSChina$446M-33%-43%-18%n/an/an/a
Neuca NEU.WAPoland$795M-9%+8%2%15.3×5.3%+8.1%
Gongwin Biopharm 6617.TWOTaiwan$412M+87%+12%-530%n/an/an/a
Shenzhen Neptunus Bioengineering 000078.SZChina$411M-48%-22%-1%n/a58.3%-7.8%
Excelsior Medical 4104.TWTaiwan$404M+5%+11%8%n/a-1.2%+5.7%
Vital KSK 3151.TJapan$399M-1%+3%0%n/a4.7%+2.6%
Shanghai Haohai Biological Technology 688366.SSChina$878M-24%-9%-2%16.2×16.9%+13.2%
Entero Healthcare Solutions ENTERO.NSIndia$925M+60%+35%4%47.7×24.7%+29.9%
Arjo ARJO-B.STSweden$974M+42%0%8%21.1×-1.0%+3.9%
Guangxi LiuYao 603368.SSChina$975M+1%+2%5%9.5×-9.7%+6.0%
Shanghai Universal Biotech 301166.SZChina$337M-15%+15%-4%25.3×n/an/a
Nanjing Pharmaceutical 600713.SSChina$999M-2%+3%2%n/an/an/a
Nagaileben 7447.TJapan$319M0%+1%21%18.2×-12.7%-0.4%
Shanghai C and D INNOSTIC Medical Technology 301584.SZChina$1.06B-33%+8%3%n/a-2.7%+17.9%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%n/an/an/a
AS ONE 7476.TJapan$1.10B+25%+10%12%18.4×0.0%+6.3%
Shinva Medical Instrument 600587.SSChina$1.10B-10%+6%5%13.4×-6.9%+1.2%

Questions

Which companies are Arata's closest peers?
The cockpit's peer set: Shanghai New World (600628.SS), GKHT Medical Technology (301370.SZ), Shanghai Lily & Beauty Cosmetics (605136.SS), Thalys Medical Technology (603716.SS), Neuca (NEU.WA), Gongwin Biopharm (6617.TWO), Shenzhen Neptunus Bioengineering (000078.SZ), Excelsior Medical (4104.TW).
Is Arata expensive compared with its peers?
On forward p/e it trades at 12.0× against a peer median of 18.2×, 2nd cheapest of 10 in its peer set. For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -10 pp: the price already allows for a slowdown.
How has Arata stock performed?
Over six months to 18 Nov 2026 the shares returned -2.5% against -5.4% for the median peer; over one year -13.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.